FiercePharma13d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now?
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
FierceBiotech12d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
BioSpace13d
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
FiercePharma7d
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Biogen Inc. stock underperforms Friday when compared to competitors
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Breaking Down Biogen: 18 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
BioSpace3d
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...